Fragile histidine triad protein, WW domain-containing oxidoreductase protein wwox, and activator protein 2γ expression levels correlate with basal phenotype in breast cancer

Cancer

Volumn 115, Issue 4, 2009, Pages 899-908

  Guler, Gulnur ^a   Huebner, Kay ^b,c   Himmetoglu, Cigdem ^a   Jimenez, Rafael E ^b   Costinean, Stefan ^b   Volinia, Stefano ^b   Pilarski, Robert T ^b   Hayran, Mutlu ^a   Shapiro, Charles L ^b  

^a HACETTEPE UNIVERSITY   (Turkey)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

Activator protein 2 transcription factors; Breast cancer subtypes; Common fragile sites; Fragile histidine triad protein; Triple negative breast cancers; Ww domain containing protein

Indexed keywords

CYTOKERATIN 5; CYTOKERATIN 6; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FRAGILE HISTIDINE TRIAD PROTEIN; OXIDOREDUCTASE; PROTEIN WWOX; TRANSCRIPTION FACTOR AP 2; TRANSCRIPTION FACTOR AP 2 ALPHA; TRANSCRIPTION FACTOR AP 2 GAMMA; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; CARCINOGENESIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA DAMAGE; DNA REPAIR; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; STAINING; TISSUE MICROARRAY; TUMOR CELL; TUMOR DIFFERENTIATION;

ACID ANHYDRIDE HYDROLASES; ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, BASAL CELL; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CELL DIFFERENTIATION; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; KERATIN-5; KERATIN-6; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; OXIDOREDUCTASES; PHENOTYPE; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TISSUE ARRAY ANALYSIS; TRANSCRIPTION FACTOR AP-2; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 60849092546     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24103     Document Type: Article

References (39)

1. Durkin SG, Ragland RL, Arlt MF, et al. Replication stress induces tumor-like microdeletions in FHIT/FRA3B. Proc Natl Acad Sci USA. 2008;105:246-251.
2. Tsantoulis PK, Kotsinas A, Sfikakis PP, et al. Oncogene- induced replication stress preferentially targets common fragile sites in preneoplastic lesions. A genome-wide study. Oncogene. 2008;27:3256-3264.
3. Thavathiru E, Ludes-Meyers JH, MacLeod MC, Aldaz CM. Expression of common chromosomal fragile site genes, WWOX/FRA16D and FHIT/FRA3B is downregulated by exposure to environmental carcinogens, UV, and BPDE but not by IR. Mol Carcinog. 2005;44:174-182.
4. Guler G, Uner A, Guler N, et al. The fragile genes, FHIT and WWOX, are coordinately inactivated in invasive breast cancer: correlations with clinical features. Cancer. 2004;100: 1605-1614.
5. Guler G, Uner A, Guler N, et al. Concordant loss of fragile genes, Fhit and Wwox, in breast cancer development. Pathol Int. 2005;55:471-478.
6. Guler G, Iliopoulos D, Guler N, et al. Wwox and Ap2γ expression levels predict tamoxifen response. Clin Cancer Res. 2007;13:6115-6121.
7. Nunez MI, Ludes-Meyers J, Abba MC, et al. Frequent loss of WWOX expression in breast cancer: correlation with estrogen receptor status. Breast Cancer Res Treat. 2005;89:99-105.
8. Sbrana I, Veroni F, Nieri M, et al. Chromosomal fragile sites FRA3B and FRA16D show correlated expression and association with failure of apoptosis in lymphocytes from patients with thyroid cancer. Genes Chromosomes Cancer. 2006;45:429-436.
9. Ishii H, Vecchione A, Furukawa Y, et al. Expression of FRA16D/WWOX and FRA3B/FHIT genes in hematopoietic malignancies. Mol Cancer Res. 2003;1:940-947.
10. Aqeilan RI, Palamarchuk A, Weigel RJ, et al. Physical and functional interactions between the Wwox tumor suppressor protein and the AP-2gamma transcription factor. Cancer Res. 2004;64:8256-8261.
11. Aqeilan RI, Donati V, Palamarchuk A, et al. WW domain- containing proteins, WWOX and YAP, compete for interaction with ErbB-4 and modulate its transcriptional function. Cancer Res. 2005;65:6764-6772.
12. Bosher JM, Totty NF, Hsuan JJ, et al. A family of AP-2 proteins regulates c-erbB-2 expression in mammary carcinoma. Oncogene. 1996;17:1701-1707.
13. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747-752.
14. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98:10869-10874.
15. Reis-Filho JS, Tutt ANJ. Triple negative tumours: a critical review. Histopathology. 2008;52:108-118.
16. Yehiely F, Moyano JV, Evans RE, et al. Deconstructing the molecular portrait of basal-like breast cancer. Trends Mol Med. 2006;12:537-544.
17. Cleator S, Heller W, Coombs RC. Triple-negative breast cancer: therapeutic options. Lancet Oncol. 2007;8:235-244.
18. Turner NC, Reis-Filho JS, Russell AM, et al. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene. 2006;26:2126-2132.
19. Turner NC, Reis-Filho JS. Basal-like breast cancer and the BRCA1 phenotype. Oncogene. 2006;25:5846-5853.
20. Nielson TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10:5367-5374.
21. Cheang MC, Voduc D, Bajdik C, et al. Basal-like breast cancer defined by 5 biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res. 2008;14:1368-1376.
22. Fong LY, Fidanza V, Zanesi N, et al. Muir-Torre-like syndrome in Fhit-deficient mice. Proc Natl Acad Sci USA. 2000;97:4742-4747.
23. Zanesi N, Fidanza V, Fong LY, et al. The tumor spectrum in FHIT-deficient mice. Proc Natl Aca Sci USA. 2001;98:10250-10255.
24. Aqeilan RI, Trapasso F, Hussain S, et al. Targeted deletion of Wwox reveals a tumor suppressor function. Proc Natl Acad Sci USA. 2007;104:3949-3954.
25. Turner BC, Ottey M, Zimonjic DB, et al. The fragile histidine triad/common chromosome fragile site 3B locus and repair-deficient cancers. Cancer Res. 2002;62:4054-4060.
26. Gorgoulis VG, Vassiliou LV, Karakaidos P, et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature. 2005;434:907-913.
27. Bartkova J, Horejsi Z, Koed K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature. 2005;434:864-870.
28. Bartek J, Bartkova J, Lukas J. DNA damage signalling guards against activated oncogenes and tumour progression. Oncogene. 2007;26:7773-7779.
29. Ishii H, Mimori K, Inoue H, et al. Fhit modulates the DNA damage checkpoint response. Cancer Res. 2006;66:11287-11292.
30. Ishii H, Wang Y, Huebner K. A Fhit-ing role in the DNA damage checkpoint response. Cell Cycle. 2007;6:1044-1048.
31. Pichiorri F, Ishii H, Okumura H, et al. Molecular parameters of genome instability: roles of fragile genes at common fragile sites. J Cell Biochem. 2008;104:1525-1533.
32. Becker K, Goldberg M, Helmbold P, et al. Deletions of BRCA1/2 and p53 R248W gain-of-function mutation suggest impaired homologous recombination repair in fragile histidine triad-negative sebaceous gland carcinomas. Br J Dermatol. 2008;159:1282-1289.
33. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434:913-917.
34. Farmer H, McCabe R, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434:917-921.
35. O'Connor MJ, Martin NMB, Smith GCM. Targeted cancer therapies based on the inhibition of DNA strand break repair. Oncogene. 2007;26:7816-7824.
36. Verlinden L, Vandem Bempt I, Eelen G, et al. The E2F- regulated gene Chk1 is highly expressed in triple-negative estrogen receptor-/progesterone receptor-/Her1 -breast carcinomas. Cancer Res. 2007;67:6574-6581.
37. Iliopoulos D, Guler G, Han SY, et al. Roles of FHIT and WWOX fragile genes in cancer. Cancer Lett. 2006;232:27-36.
38. Liu S, Ginestier C, Charafe-Jauffret E, et al. BRCA1 regulates human mammary stem/progenitor cell fate. Proc Natl Acad Sci USA. 2008;105:1680-1685.
39. Ishii H, Mimori K, Ishikawa K, et al. FHIT-deficient hematopoietic stem cells survive hydroquinone treatment long-term, carrying precancerous alterations. Cancer Res. 2008;68:3662-3670.